Propanc Biopharma Inc (NASDAQ:PPCB) Short Interest Update

Propanc Biopharma Inc (NASDAQ:PPCB) was the target of a large decrease in short interest in June. As of June 30th, there was short interest totaling 16,903 shares, a decrease of 95.2% from the June 15th total of 352,559 shares. Based on an average daily trading volume, of 206,327 shares, the short-interest ratio is presently 0.1 days. Approximately 1.0% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Propanc Biopharma from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of “Sell”.

Propanc Biopharma Stock Performance

PPCB traded down $0.17 during trading on Friday, reaching $1.61. 218,210 shares of the company traded hands, compared to its average volume of 3,221,563. Propanc Biopharma has a 12-month low of $1.30 and a 12-month high of $270.25. The firm has a fifty day simple moving average of $1.82 and a 200 day simple moving average of $4.62. The company has a market cap of $3.67 million, a P/E ratio of -0.07 and a beta of 3.49.

Propanc Biopharma announced that its Board of Directors has initiated a share repurchase plan on Thursday, June 11th that authorizes the company to repurchase $5.00 million in outstanding shares. This repurchase authorization authorizes the company to purchase up to 162.3% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board believes its stock is undervalued.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Propanc Biopharma stock. Virtu Financial LLC acquired a new stake in shares of Propanc Biopharma Inc (NASDAQ:PPCB) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 41,677 shares of the company’s stock, valued at approximately $71,000. Virtu Financial LLC owned approximately 0.33% of Propanc Biopharma as of its most recent SEC filing.

Propanc Biopharma Company Profile

Propanc Biopharma Ltd is a clinical-stage biotechnology company focused on developing novel biologic drug candidates for the treatment of invasive and metastatic cancers. The company’s core technology centers on proprietary formulations of recombinant human proteolytic enzymes designed to degrade the dense extracellular matrix that surrounds solid tumors. By reducing stromal barriers, these candidates are intended to enhance the delivery and efficacy of co-administered chemotherapies, immunotherapies or other targeted agents.

The company’s lead program, known as PRP, comprises a combination of modified pancreatic proteases that have demonstrated promising preclinical activity in degrading tumor stroma and inhibiting tumor growth.